University of Southern California, Rancho Los Amigos National Rehabilitation Center, Los Angeles, CA 90033, USA.
Curr Urol Rep. 2010 Nov;11(6):432-9. doi: 10.1007/s11934-010-0135-3.
Overactive bladder (OAB) is a highly prevalent syndrome defined as "urinary urgency, usually accompanied by frequency and nocturia with or without urgency urinary incontinence, in the absence of urinary tract infection or other obvious pathology." It is known to generate a large degree of bother and can lead to significant morbidity. Augmentation cystoplasty (AC) historically has been reserved for patients refractory to conservative management. Over time, the treatment options for OAB have grown. We now have multiple pharmacological agents approved by the US Food and Drug Administration to treat OAB. In addition, neuromodulation and botulinum toxin now are viable options for patients who have suboptimal outcomes after treatment with anticholinergics and/or pelvic floor behavioral therapy. This may suggest that AC no longer is utilized as a mainstay therapy for OAB. However, despite these many possible treatment options, AC remains an important, time-tested tool in the armamentarium of the urologist to combat the patient with refractory OAB.
膀胱过度活动症（OAB）是一种高度普遍的综合征，定义为“在没有尿路感染或其他明显病理的情况下出现尿急，通常伴有尿频和夜尿，伴有或不伴有急迫性尿失禁”。它被认为会产生很大的困扰，并可能导致严重的发病率。膀胱扩大术（AC）历史上仅保留给对保守治疗有抵抗力的患者。随着时间的推移，OAB 的治疗选择已经增加。现在，我们有多种已被美国食品和药物管理局批准用于治疗 OAB 的药物。此外，对于在接受抗胆碱能药物和/或盆底行为疗法治疗后效果不佳的患者，神经调节和肉毒毒素现在也是可行的选择。这可能表明 AC 不再是治疗 OAB 的主要方法。然而，尽管有许多可能的治疗选择，AC 仍然是泌尿科医生手中对抗难治性 OAB 患者的一种重要的、久经考验的工具。
